Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Collaborates with RemeGen to Test PD-1/ADC Combination for Solid Tumors

publication date: Jun 26, 2023

Suzhou Innovent Biologics formed a clinical collaboration with RemeGen that will test its PD-1 inhibitor with one of two RemeGen (SHA: 688331; HK: 09995) ADC assets for advanced solid tumors. Innovent will contribute TYVYT® (sintilimab injection), which has been approved in China for seven oncology indications. RemeGen will add either RC88, a novel mesothelin(MSLN)-targeting antibody-drug conjugate, or RC108, a novel c-Met-targeting ADC. RemeGen will be responsible for conducting Phase I/IIa clinical studies to assess the anti-tumor activity and safety of the combination. More details....

Stock Symbols: (HK: 01801) (SHA: 688331; HK: 09995)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here